Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$23.21 - $27.24 $142,602 - $167,362
-6,144 Reduced 25.45%
18,000 $433,000
Q1 2024

May 15, 2024

SELL
$26.4 - $32.56 $738,355 - $910,638
-27,968 Reduced 53.67%
24,144 $653,000
Q4 2023

Feb 14, 2024

SELL
$23.37 - $28.68 $691,471 - $848,583
-29,588 Reduced 36.22%
52,112 $1.45 Million
Q2 2023

Aug 14, 2023

BUY
$28.34 - $33.63 $495,950 - $588,525
17,500 Added 27.26%
81,700 $2.56 Million
Q1 2023

May 15, 2023

BUY
$25.31 - $29.02 $726,397 - $832,874
28,700 Added 80.85%
64,200 $1.81 Million
Q4 2022

Feb 14, 2023

BUY
$21.94 - $26.24 $778,870 - $931,520
35,500 New
35,500 $927,000
Q2 2022

Aug 11, 2022

BUY
$26.4 - $30.54 $850,080 - $983,388
32,200 Added 42.93%
107,200 $3.19 Million
Q1 2022

May 13, 2022

BUY
$23.07 - $27.99 $1.73 Million - $2.1 Million
75,000 New
75,000 $1.97 Million
Q1 2020

May 14, 2020

SELL
$13.06 - $21.24 $2.2 Million - $3.58 Million
-168,400 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$17.29 - $21.74 $2.91 Million - $3.66 Million
168,400 New
168,400 $3.44 Million
Q3 2018

Nov 13, 2018

SELL
$38.6 - $46.12 $1.26 Million - $1.51 Million
-32,650 Closed
0 $0
Q2 2018

Aug 07, 2018

SELL
$40.56 - $51.36 $740,220 - $937,320
-18,250 Reduced 35.85%
32,650 $1.34 Million
Q1 2018

May 09, 2018

SELL
$53.61 - $67.26 $42,888 - $53,808
-800 Reduced 1.55%
50,900 $2.95 Million
Q4 2017

Feb 14, 2018

SELL
$47.69 - $55.39 $209,836 - $243,716
-4,400 Reduced 7.84%
51,700 $2.83 Million
Q3 2017

Nov 13, 2017

SELL
$49.16 - $54.45 $4.01 Million - $4.44 Million
-81,500 Reduced 59.23%
56,100 $2.85 Million
Q2 2017

Aug 14, 2017

BUY
N/A
137,600
137,600 $7.98 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.55B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.